Urea breath test

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

Retrieved on: 
Friday, July 23, 2021

With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.

Key Points: 
  • With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.
  • We look forward to supporting Otsukas customers with the gastrointestinal expertise and world class customer service Meridian is known for.
  • Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
  • Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.

Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

Retrieved on: 
Thursday, April 30, 2020

Annually there are between 500,000 and 850,000 new cases of peptic ulcer disease and over one million ulcer-related hospitalizations.

Key Points: 
  • Annually there are between 500,000 and 850,000 new cases of peptic ulcer disease and over one million ulcer-related hospitalizations.
  • Jack Kenny, Chief Executive Officer, said, We are excited to complete the acquisition of Exalenz Bioscience Ltd. and its H. pylori urea breath testing systems.
  • Meridian will provide more background on Exalenz and the strategic rationale on the Companys earnings call on May 8, 2020 at 10:00am Eastern Time.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Retrieved on: 
Wednesday, February 19, 2020

With this acquisition, Meridian will be adding Exalenzs flagship BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori, often associated with peptic ulcers and gastric cancer.

Key Points: 
  • With this acquisition, Meridian will be adding Exalenzs flagship BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori, often associated with peptic ulcers and gastric cancer.
  • Jack Kenny, Chief Executive Officer, commented, Our focus has been to drive our strategy to re-position our Diagnostics business for sustainable, long-term growth.
  • We are very excited to be adding yet another state-of-the-art technology to our portfolio and thrilled to welcome Exalenz to the Meridian family.
  • We also look forward to collaborating with the Meridian R&D team in our on-going advancement of this leading platform.

Global Helicobacter Pylori Non-Invasive Testing Market to 2027: Analysis & Forecast by Test, Test Method, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, September 20, 2019

The "Helicobacter Pylori Non-Invasive Testing Market to 2027 - Global Analysis and Forecast by Test; Test Method; End User and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Helicobacter Pylori Non-Invasive Testing Market to 2027 - Global Analysis and Forecast by Test; Test Method; End User and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.7 Mn in 2018.
  • The Helicobacter pylori non-invasive testing market is estimated to grow with a CAGR of 4.1% from 2019-2027.
  • Global Helicobacter pylori non-invasive testing market was segmented by test type, test method and end user.

The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.70 Mn in 2018

Retrieved on: 
Wednesday, September 18, 2019

The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.70 Mn in 2018.

Key Points: 
  • The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.70 Mn in 2018.
  • The Helicobacter pylori non-invasive testing market is estimated to grow with a CAGR of 4.1% from 2019-2027.
  • The global Helicobacter pylori infection rate in female was found to be 42.7% as compared to 46.3% in males.
  • Hence, driving the growth of the Helicobacter pylori Non-Invasive Testing Market during the forecast period.

Global Peptic Ulcer Testing Industry

Retrieved on: 
Monday, June 25, 2018

Table 1: Prevalence of H. Pylori Infection by Geographic Region - Prevalence Rate in % for Africa, Asia, Australasia, Eastern Europe, Latin America, North America and Western Europe

Key Points: 
  • Table 1: Prevalence of H. Pylori Infection by Geographic Region - Prevalence Rate in % for Africa, Asia, Australasia, Eastern Europe, Latin America, North America and Western Europe
    Diagnosis of Peptic Ulcer Disease - Testing for H. Pylori Infection
    Rising Incidence of Gastric Cancer: Potential Opportunities for H. Pylori Testing
    A Review of Select H. Pylori Tests
    Table 4: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    Table 5: Global Aging Population in Select Regions/ Countries: Population of 60+ Individuals as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    Rapid Tests - Enabling Faster Testing for H. Pylori Infection
    Rapid Urease Tests: Most Useful Invasive Test for H. Pylori Detection
    Cost Influencing Choice of Testing for H. Pylori
    DVC-FISH Test Offers Positive Results in Detecting Viable H. Pylori Cells in Fecal Samples
    Antibody Tests Not Recommended for Children; Biopsy Tests More Pertinent
    3.
  • PEPTIC ULCERS - THE DISEASE, CAUSES, SYMPTOMS, TYPES, DIAGNOSIS, AND TREATMENT

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market to be Worth US$ 700 Mn by 2026, Says TMR

Retrieved on: 
Monday, June 11, 2018

Among test methods, the laboratory-based tests segment of the global helicobacter pylori (h. pylori) non-invasive testing market is estimated to witness a significant growth during the forecast period.

Key Points: 
  • Among test methods, the laboratory-based tests segment of the global helicobacter pylori (h. pylori) non-invasive testing market is estimated to witness a significant growth during the forecast period.
  • The helicobacter pylori (H. pylori) non-invasive testing market in Asia Pacific is estimated to expand at a significant CAGR of 4.52% during the forecast period.
  • The helicobacter pylori (H. pylori) non-invasive testing market in North America is likely to register a CAGR of 3.62% during the forecast period.
  • Request a Sample of Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: https://www.transparencymarketresearch.com/helicobacter-pylori-non-invas...
    Key players to continue leading global helicobacter pylori (H. pylori) non-invasive testing market
    Prominent players operating in the global helicobacter pylori (h. pylori) non-invasive testing market are DiaSorin S.p.A., Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Alere, Thermo Fisher Scientific, Biomerica, Inc., Certest Biotec S.L., Sekisui Diagnostics, CorisBioconcept SPRL and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.